Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Justin Grenet, Neela Easwar, Akriti G. Jain, Madelyn Burkart, Xiaoyue Ma, Paul Christos, Ellen K. Ritchie, Michael Samuel, Justin D. Kaner, Jonathan Canaani, Aaron D. Goldberg, Shira N. Dinner, Kendra L. Sweet, Gail J. Roboz, Pinkal Desai

Blood (2024) 144 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2024-206340

Published: 2024

Journal Articles

Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab

Cara Rosenbaum, Michaela Liedtke, Paul Christos, Hyemin Kim, Kathleen Pogonowski, Natalie Agudo, Bruna Barroso, Anthony Shelton, Samantha Reilly, Courtney Gadbois, John Mark Sloan, Vaishali Sanchorawala, Anita D'Souza

Blood (2023) 142 (Supplement 1): 3402.

https://doi.org/10.1182/blood-2023-191133

Published: 2023

Journal Articles

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Jia Ruan, Peter Martin, Paul Christos, Leandro Cerchietti, Wayne Tam, Bijal Shah, Stephen J. Schuster, Amelyn Rodriguez, David Hyman, Maria Nieves Calvo-Vidal, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, Morton Coleman, John P. Leonard

Blood (2018) 132 (19): 2016–2025.

https://doi.org/10.1182/blood-2018-07-859769

Published: 2018

Journal Articles

The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis

Richard T. Silver, Ariella Barel, Elena Lascu, BA,MA, Ellen K. Ritchie, MD, Gail J. Roboz, MD, Paul Christos, Attilio Orazi, MD, Duane C Hassane, PhD, Wayne Tam, MD PhD, Nicholas C.P. Cross, PhD

Blood (2016) 128 (22): 944.

https://doi.org/10.1182/blood.V128.22.944.944

Published: 2016

Journal Articles

Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

Jia Ruan, MD PhD, Peter Martin, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Sonali M. Smith, MD, Richard R Furman, MD, Paul Christos, DrPH, Amelyn Rodriguez, RN, Louisa Drake, Jakub Svoboda, MD, Jessica Lewis, PA-C, Orel Katz, PA-C, Morton Coleman, MD, John P. Leonard, MD

Blood (2014) 124 (21): 625.

https://doi.org/10.1182/blood.V124.21.625.625

Published: 2014

Journal Articles

Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML)

Ellen K. Ritchie, MD, Danielle C. Marshall, B.A., Molly D. Greenberg, B.S., Tania J. Curcio, R.N, Ashley E. Giambrone, PhD, Paul Christos, DrPH, Eric J. Feldman, MD, Joseph M. Scandura, MD PhD, Gail J. Roboz, MD

Blood (2014) 124 (21): 3689.

https://doi.org/10.1182/blood.V124.21.3689.3689

Published: 2014

Journal Articles

Adult Transfusion-Dependent Thalassemia Patients in 2014: A Single Center Cross-Sectional Analysis of Health Outcomes

Ersilia M DeFilippis, BA, Patricia-Jane Giardina, MD, Dorothy Kleinert, NP, Maria Vogiatzi, MD, Paul Christos, DrPH, John C. Chapin, MD

Blood (2014) 124 (21): 4893.

https://doi.org/10.1182/blood.V124.21.4893.4893

Published: 2014

Journal Articles

Fracture Prevalence in Adults with Transfusion-Dependent Thalassemia Is Related to Osteoporosis and Age

John C. Chapin, MD, Maria Vogiatzi, MD, Dorothy Kleinert, NP, Ersilia DeFilippis, Paul Christos, DrPH, Patricia Giardina, MD

Blood (2014) 124 (21): 4902.

https://doi.org/10.1182/blood.V124.21.4902.4902

Published: 2014

Journal Articles

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Hesam Hekmatjou, MD, Gail J. Roboz, MD, Ellen K. Ritchie, MD, Sangmin Lee, MD, Pinkal Desai, MD, Joseph M. Scandura, MD PhD, Sandra Allen-Bard, ANP, BS, BSN, MSN, NP, Paul Christos, DrPH, Richard T. Silver, MD, Eric J. Feldman, MD

Blood (2014) 124 (21): 1811.

https://doi.org/10.1182/blood.V124.21.1811.1811

Published: 2014

Journal Articles

Outcomes In Adult Hemophilia and Von Willebrand Disease Patients Undergoing Surgical and Invasive Procedures

John C. Chapin, MD, Jacqueline Bamme, MD, Fraustina Hsu, Paul Christos, Maria Teresa De Sancho, MD, MSc

Blood (2013) 122 (21): 1120.

https://doi.org/10.1182/blood.V122.21.1120.1120

Published: 2013

Journal Articles

Combination Biologic Therapy Without Chemotherapy As Initial Treatment For Mantle Cell Lymphoma: Multi-Center Phase II Study Of Lenalidomide Plus Rituximab

Jia Ruan, MD, PhD, Peter Martin, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Sonali M. Smith, MD, Richard R. Furman, MD, Paul Christos, Amelyn Rodriguez, RN, Paige Wolstencroft, Jakub Svoboda, MD, Alison Bender, PA-C, Jessica Lewis, PA-C, Morton Coleman, MD, John P. Leonard, MD

Blood (2013) 122 (21): 247.

https://doi.org/10.1182/blood.V122.21.247.247

Published: 2013

Journal Articles

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

Adriana Rossi, Tomer Mark, David Jayabalan, Paul Christos, Faiza Zafar, Karen Pekle, Roger Pearse, Selina Chen-Kiang, Morton Coleman, Ruben Niesvizky

Blood (2013) 121 (11): 1982–1985.

https://doi.org/10.1182/blood-2012-08-448563

Published: 2013

Includes: Supplemental data

Journal Articles

Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL

Rebecca L. Elstrom, MD, Leandro Cerchietti, MD, Peter Martin, MD, Richard R. Furman, MD, ShaoNing Yang, MS, Jia Ruan, MD, PhD, Paul Christos, Morton Coleman, MD, Amelyn Rodriguez, Madhu Mazumdar, Ari Melnick, MD, John P. Leonard, MD

Blood (2012) 120 (21): 3706.

https://doi.org/10.1182/blood.V120.21.3706.3706

Published: 2012

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Rebecca L. Elstrom, MD, John P. Leonard, MD, Paul Christos, Peter Martin, MD, Daniel Lebovic, MD, Joseph Osborne, Stanley J. Goldsmith, June Greenberg, RN, Richard R. Furman, MD, Jia Ruan, MD, PhD, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 1636.

https://doi.org/10.1182/blood.V120.21.1636.1636

Published: 2012

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Rebecca Elstrom, MD, John P. Leonard, MD, Stanley J. Goldsmith, Paul Christos, Peter Martin, Joseph Osborne, Daniel Lebovic, MD, Ramsey Abdallah, CRC, June Greenberg, Richard R. Furman, MD, Jia Ruan, MD, PhD, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2011) 118 (21): 3712.

https://doi.org/10.1182/blood.V118.21.3712.3712

Published: 2011

Journal Articles

Intensive Treatment Strategies May Not Provide Superior Outcomes in Mantle Cell Lymphoma: Overall Survival Exceeding Seven Years in a Large Cohort of Patients Managed Primarily with Conservative Therapies.

Peter Martin, MD, Amy Chadburn, MD, Paul Christos, Richard R. Furman, MD, Jia Ruan, Maureen A. Joyce, Patricia Glynn, Ruben Niesvizky, Eric J. Feldman, Tsiporah B. Shore, Michael W. Schuster, Scott Ely, Daniel Knowles, Selina Chen-Kiang, Morton Coleman, John P. Leonard

Blood (2007) 110 (11): 1362.

https://doi.org/10.1182/blood.V110.11.1362.1362

Published: 2007

Journal Articles

FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma.

Lale Kostakoglu, MD, Stanley J. Goldsmith, MD, Amy Chadburn, MD, Erez Vidan, MD, Michael Schuster, MD, Paul Christos, M.S., MPH, Morton Coleman, MD

Blood (2005) 106 (11): 1927.

https://doi.org/10.1182/blood.V106.11.1927.1927

Published: 2005

NARROW

Assessing Role of Comorbidities in Treatment Selection for Older Patients with Acute Myeloid Leukemia

Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/ Refractory Light Chain Amyloidosis Previously Exposed to Daratumumab

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis

Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

Comprehensive Geriatric Assessment Does Not Predict Overall Survival in Older Patients with Acute Myeloid Leukemia (AML)

Adult Transfusion-Dependent Thalassemia Patients in 2014: A Single Center Cross-Sectional Analysis of Health Outcomes

Fracture Prevalence in Adults with Transfusion-Dependent Thalassemia Is Related to Osteoporosis and Age

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Outcomes In Adult Hemophilia and Von Willebrand Disease Patients Undergoing Surgical and Invasive Procedures

Combination Biologic Therapy Without Chemotherapy As Initial Treatment For Mantle Cell Lymphoma: Multi-Center Phase II Study Of Lenalidomide Plus Rituximab

BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Intensive Treatment Strategies May Not Provide Superior Outcomes in Mantle Cell Lymphoma: Overall Survival Exceeding Seven Years in a Large Cohort of Patients Managed Primarily with Conservative Therapies.

FDG-PET May Be Helpful in the Determination of Transformation to an Aggressive Subtype in Low-Grade Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only